尼洛替尼治疗慢性粒细胞白血病的临床观察

Clinical effects of nilotinib on chronic myelogenous leukemia

观察二代酪氨酸激酶抑制剂(TKI)尼洛替尼对14例伊马替尼耐药或不耐受的慢性粒细胞白血病(CML)患者的疗效及不良反应。14例患者有10例(71.4%)获得血液学完全缓解(CHR),其中2例(20%)缓解后复发。14例患者中2例(14.3%)获得完全遗传学缓解(CCyR),4例(28.6%)获部分遗传学缓解(PCyR),其中1例(16.7%)缓解后3个月复发。提示尼洛替尼对伊马替尼治疗耐药或不耐受的CML患者有较高的血液学及遗传学缓解率。

To observe the efficacy and adverse reactions of a second-generation tyrosine kinase inhibitor（TKI） nilotinib on 14 chronic myelogenous leukemia（CML） cases who were resistance or intolerance of imatinib therapy.10 cases（71.4%） achieved complete hematologic remission（CHR）,2 cases（20%） relapsed after remission.2 cases（14.3%） were complete cytogenetic remission（CCyR）,4 cases（28.6%） were partial cytogenetic remission（PCyR）,of which 1 case（16.7%） relapsed in 3 months after remission.Nilotinib is a effective drug for the resistance or intolerance of imatinib in patients with CML,which has a higher remission rate of hematology and genetics.